In the present study, we demonstrated that fluspirilene, selected from five drug libraries composed of 1,301 compounds, suppressed the proliferation and invasion of patient-derived GSCs, glioma cells, and mouse brain tumor via inactivation of STAT3, suggesting that fluspirilene has a novel therapeutic potential against GBM as a repositioned drug. The gene discussed is STAT3; the disease is brain neoplasm.